Key result
Amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide reduced blood pressure across high-risk subgroups, including elderly patients (-32.2/-14.3 mmHg and -38.5/-16.5 mmHg, respectively).
Why the study?
Do amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide single-pill combinations reduce blood pressure in high-risk hypertensive patients in routine clinical practice?
Observational (n=9,794)
Yes
Do amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide single-pill combinations reduce blood pressure in high-risk hypertensive patients in routine clinical practice?
Single-pill combinations of amlodipine/valsartan with or without hydrochlorothiazide provide clinically relevant blood pressure reductions across diverse, high-risk hypertensive subgroups in routine clinical practice.
Supports BP reductions with these combinations in high-risk patients; leaves open randomized confirmation before practice change.
BACKGROUND: The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy. METHODS: Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed. RESULTS: Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (-32.2/-14.3 mmHg and -38.5/-16.5 mmHg), obese patients (-32.2/-17.9 mmHg and -38.5/-18.4 mmHg), diabetic patients (-30.3/-16.1 mmHg and -34.4/-16.6 mmHg), and patients with isolated systolic hypertension (-25.5/-4.1 mmHg and -30.2/-5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated. CONCLUSION: This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/ HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Assaad‐Khalil et al. (2015) conducted an observational in Hypertension (n=9,794). Amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide was evaluated on Changes in mean sitting systolic BP and mean sitting diastolic BP. Amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide reduced blood pressure across high-risk subgroups, including elderly patients (-32.2/-14.3 mmHg and -38.5/-16.5 mmHg, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: